Digital Repository

Cerebral microbleeds and stroke: more questions than answers

Show simple item record

dc.contributor.author Ranawaka, U.K.
dc.date.accessioned 2022-07-21T05:34:19Z
dc.date.available 2022-07-21T05:34:19Z
dc.date.issued 2021
dc.identifier.citation Sri Lanka Journal of Neurology.2021;8(1):10–14. en_US
dc.identifier.issn 2279-2295
dc.identifier.uri http://repository.kln.ac.lk/handle/123456789/24938
dc.description.abstract With the widespread availability of MRI scanning, cerebral microbleeds (CMBs) are being increasingly recognized in patients with stroke and in healthy individuals. As CMBs are commonly viewed as markers of increased risk of intracerebral haemorrhage (ICH), there are concerns regarding the use of antithrombotic agents (antiplatelets, and especially anticoagulants) in the presence of CMBs, even in patients at high risk of ischaemic events. The use of antiplatelet or anticoagulant therapy in the presence of CMBs, balancing the risk of possible intracranial bleeding, is one of the most contentious contemporary issues in stroke medicine. en_US
dc.language.iso en en_US
dc.publisher Association of Sri Lankan Neurologists en_US
dc.subject Cerebral microbleeds en_US
dc.subject Stroke en_US
dc.subject Intracerebral haemorrhage en_US
dc.title Cerebral microbleeds and stroke: more questions than answers en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search Digital Repository


Browse

My Account